1-(3-iodo-propyl)-piperidine | 359772-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(3-iodo-propyl)-piperidine
• 英文别名: 1-(3-Jod-propyl)-piperidin；1-(3-Iodopropyl)piperidine
• CAS: 359772-96-6
• 化学式: C₈H₁₆IN
• 分子量: 253.126
• InChiKey: LJTSJFRSRPUQBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(3-iodo-propyl)-piperidine 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Dunlop, Journal of the Chemical Society, 1912, vol. 101, p. 2002

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢碘酸 作用下， 生成 1-(3-iodo-propyl)-piperidine
  参考文献：
  名称：

  Gabriel; Colmann, Chemische Berichte, 1906, vol. 39, p. 2886,2887

  摘要：

  DOI：

文献信息

• [EN] NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS DE CYCLOSPORINE ET LEURS UTILISATIONS
  申请人：S&T GLOBAL INC

  公开号：WO2017200984A1

  公开（公告）日：2017-11-23

  A compound of the Formula (I) is disclosed: (I) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification. Also described are a pharmaceutical composition comprising the same and a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, and liver, and kindey diseases, and hair loss using the same.

  公开了化合物的公式（I）：（I）或其药学上可接受的盐，其中符号如规范中定义。还描述了包含相同化合物的药物组合物，以及使用该药物组合物治疗或预防病毒感染、炎症、干眼症、中枢神经障碍、心血管疾病、癌症、肥胖症、糖尿病、肌肉萎缩症、肺部和肝脏疾病、肾脏疾病和脱发的方法。
• Design, Synthesis, and Antifungal Evaluation of Novel Quinoline Derivatives Inspired from Natural Quinine Alkaloids
  作者：Guan-Zhou Yang、Jia-Kai Zhu、Xiao-Dan Yin、Yin-Fang Yan、Yu-Ling Wang、Xiao-Fei Shang、Ying-Qian Liu、Zhong-Min Zhao、Jing-Wen Peng、Hua Liu

  DOI：10.1021/acs.jafc.9b04224

  日期：2019.10.16

  Inspired by quinine and its analogues, we designed, synthesized, and evaluated two series of quinoline small molecular compounds (a and 2a) and six series of quinoline derivatives (3a–f) for their antifungal activities. The results showed that compounds 3e and 3f series exhibited significant fungicidal activities. Significantly, compounds 3f-4 (EC50 = 0.41 μg/mL) and 3f-28 (EC50 = 0.55 μg/mL) displayed

  受奎宁及其类似物的启发，我们设计，合成和评估了两个系列的喹啉小分子化合物（a和2a）和六个系列的喹啉衍生物（3a - f）的抗真菌活性。结果表明，化合物3e和3f系列表现出显着的杀真菌活性。值得注意的是，化合物3f-4（EC 50 = 0.41μg/ mL）和3f-28（EC 50 = 0.55μg/ mL）显示出优异的体外杀真菌活性和对菌核菌的有效体内治疗作用。初步机理研究表明，化合物3f-4和3f-28可能引起细胞膜通透性改变，活性氧的积累，线粒体膜电位的丧失以及有效抑制菌核菌的发芽和形成。这些结果表明，化合物3f-4和3f-28是对抗源自天然产物的核盘菌的新型潜在杀真菌剂。
• Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them
  申请人：CERMOL S.A.

  公开号：EP1132381A1

  公开（公告）日：2001-09-12

  The present invention relates to esters of 2,2-dimethylpropionic acid having the general formula (I) or pharmacological acceptable salts thereof, as well as to pharmaceutical compositions containing said compounds and having an inhibitory activity of elastase.

  本发明涉及具有通式（I）的2,2-二甲基丙酸酯或其药理学上可接受的盐，以及含有该化合物并具有弹性蛋白酶抑制活性的药物组合物。
• THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r)
  申请人：Northwestern University

  公开号：US20170305901A1

  公开（公告）日：2017-10-26

  Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).

  揭示了治疗与混合系谱白血病基因（MLL-r）重排相关的癌症的方法，包括MLL-r白血病。这些方法通常包括给予治疗量的一个或多个治疗剂，其抑制白介素-1信号通路的一个或多个成员的生物活性，例如白介素-1受体相关激酶4（IRAK4）的抑制剂。
• BENZOFURAN COMPOUNDS, COMPOSITIONS, KITS AND/OR METHODS THEREOF
  申请人：Savannah State University

  公开号：US20150133498A1

  公开（公告）日：2015-05-14

  Benzofuran compound, composition thereof, kit thereof, and/or method thereof. A benzofuran-2-carboxamide moiety may be N-arylated and/or N-alkylated, and the resulting benzofuran compound may be a sigma receptor ligand that binds to, e.g., a σ1 receptor and/or a σ2 receptor with relatively high affinity and/or selectivity. For example, the benzofuran compound may be 5,6-dimethoxy-3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide, 3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide, or 6-methoxy-3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide. The composition may include the benzofuran compound and a pharmaceutically acceptable carrier.

  苯并呋喃化合物、其组成物、套件以及/或方法。苯并呋喃-2-羧酰胺基团可以被N-芳基化和/或N-烷基化，从而产生的苯并呋喃化合物可以是与σ1受体和/或σ2受体具有相对高亲和力和/或选择性的σ受体配体。例如，苯并呋喃化合物可以是5,6-二甲氧基-3-甲基-N-苯基-N-(3-哌啶基)丙基)苯并呋喃-2-羧酰胺、3-甲基-N-苯基-N-(3-哌啶基)丙基)苯并呋喃-2-羧酰胺或6-甲氧基-3-甲基-N-苯基-N-(3-哌啶基)丙基)苯并呋喃-2-羧酰胺。该组成物可以包括苯并呋喃化合物和药学上可接受的载体。